C. C. Zouboulis, N. Desai, L. Emtestam, R. E. Hunger, D. Ioannides et al., European S1 289 guideline for the treatment of hidradenitis suppurativa/acne inversa, J Eur Acad Dermatol, vol.290, pp.619-663, 2015.

P. Wolkenstein, A. Loundou, K. Barrau, P. Auquier, and J. Revuz, Quality of life impairment in 292 hidradenitis suppurativa. A study of 61 cases, J Am Acad Dermatol, vol.56, pp.621-624, 2007.

J. J. Kohorst, C. Hagen, C. L. Baum, and M. D. Davis, Treatment experience in a local population 294 with hidradenitis suppurativa, J Drugs Dermatol, vol.13, pp.827-858, 2014.

K. Mcmillan, Hidradenitis suppurativa: number of diagnosed patients, demographic 296 characteristics, and treatment patterns in the United States, Am J Epidemiol, vol.179, pp.1477-297, 2014.

S. Jafari, S. M. Knusel, E. Cazzaniga, S. Hunger, and R. E. , A Retrospective Cohort Study on 299 Patients with Hidradenitis Suppurativa, Dermatology, vol.234, pp.71-79, 2018.

J. R. Ingram and M. Mcphee, Management of hidradenitis suppurativa: a U.K. survey of current 301 practice, Br J Dermatol, vol.173, pp.1070-1072, 2015.

J. R. Ingram, F. Collier, D. Brown, T. Burton, J. Burton et al., British Association, p.303

, Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa, p.304

, Br J Dermatol, vol.180, pp.1009-1026, 2019.

A. Alikhan, C. Sayed, A. Alavi, R. Alhusayen, A. Brassard et al., North American 306 clinical management guidelines for hidradenitis suppurativa, p.307

, States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and 308 systemic medical management, J Am Acad Dermatol, vol.81, pp.91-101, 2019.

R. F. Magalhaes, M. C. Rivitti-machado, G. V. Duarte, R. Souto, D. H. Nunes et al.,

, Consensus on the treatment of hidradenitis suppurativa -Brazilian Society of Dermatology

, An Bras Dermatol, vol.94, pp.7-19, 2019.

H. J. Hurley, Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and 313 familial benign pemphigus : surgical approach

F. Canoui-poitrine, J. E. Revuz, P. Wolkenstein, C. Viallette, G. Gabison et al.,

, Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with 317 an analysis of factors associated with disease severity, J Am Acad Dermatol, vol.61, pp.51-58, 2009.

A. Garg, E. Neuren, D. Cha, J. S. Kirby, J. R. Ingram et al., , p.319

, Unmet Needs in Hidradenitis Suppurativa: results from the Global VOICE project, J Am, vol.320

A. Dermatol, , 2019.

H. Guet-revillet, J. P. Jais, M. N. Ungeheuer, H. Coignard-biehler, S. Duchatelet et al.,

, The Microbiological Landscape of Anaerobic Infections in Hidradenitis Suppurativa: A 323

, Prospective Metagenomic Study. Clin Infect Dis, vol.65, pp.282-91, 2017.

H. Guet-revillet, H. Coignard-biehler, J. P. Jais, G. Quesne, E. Frapy et al., Bacterial 325 pathogens associated with hidradenitis suppurativa, france, Emerg Infect Dis, vol.20, pp.1990-1998, 2014.

H. C. Ring, J. Thorsen, D. M. Saunte, B. Lilje, L. Bay et al., The Follicular Skin, vol.327

, Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls, JAMA 328 Dermatol, vol.153, pp.897-905, 2017.

O. Lambert, H. Coignard, J. P. Jais, H. Guet-revillet, S. Poiree et al., Efficacy 330 of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa, Dermatology, vol.222, pp.49-58, 2011.

D. L. Stevens, A. L. Bisno, H. F. Chambers, E. P. Dellinger, E. J. Goldstein et al.,

, Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 334 update by the infectious diseases society of America, Clin Infect Dis, vol.59, pp.147-59, 2014.

A. Leplege, E. Ecosse, J. Zeller, J. Revuz, and P. Wolkenstein, The French version of Skindex 336 (Skindex-France). Adaptation and assessment of psychometric properties

, Ann Dermatol 337 Venereol, vol.130, pp.177-83, 2003.

K. Sartorius, L. Emtestam, G. B. Jemec, and J. Lapins, Objective scoring of hidradenitis 339 suppurativa reflecting the role of tobacco smoking and obesity, Br J Dermatol, vol.161, pp.831-340, 2009.

J. Revuz, Modifications to the Sartorius score and instructions for evaluating the severity 342 of suppurative hidradenitis

, Ann Dermatol Venereol, vol.134, pp.173-177, 2007.

G. B. Jemec and P. Wendelboe, Topical clindamycin versus systemic tetracycline in the 344 treatment of hidradenitis suppurativa, J Am Acad Dermatol, vol.39, pp.971-975, 1998.

, Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin, Int J 346 Dermatol, vol.22, pp.325-333, 1983.

C. O. Mendonca and C. E. Griffiths, Clindamycin and rifampicin combination therapy for 348 hidradenitis suppurativa, Br J Dermatol, vol.154, pp.977-985, 2006.

G. Gener, F. Canoui-poitrine, J. E. Revuz, F. O. Poli, F. Gabison et al., Combination 350 therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 351 consecutive patients, Dermatology, vol.219, pp.148-54, 2009.

H. H. Der-zee, J. Boer, E. P. Prens, and G. B. Jemec, The effect of combined treatment with oral 353 clindamycin and oral rifampicin in patients with hidradenitis suppurativa, Dermatology, vol.354, pp.143-150, 2009.

H. Ochi, L. C. Tan, and H. H. Oon, The effect of oral clindamycin and rifampicin combination 356 therapy in patients with hidradenitis suppurativa in Singapore, Clin Cosmet Investig Dermatol, vol.357, pp.37-46, 2018.

C. Caro, R. D. Cannizzaro, M. V. Botti, E. , D. Raimondo et al.,

, Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: 360 Clinical and ultrasound observations, J Am Acad Dermatol, vol.80, pp.1314-1335, 2019.

V. Bettoli, S. Zauli, A. Borghi, G. Toni, S. Minghetti et al., Oral clindamycin and 362 rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 363 patients, J Eur Acad Dermatol Venereol, vol.28, pp.125-131, 2014.

C. Dessinioti, C. Zisimou, V. Tzanetakou, A. Stratigos, and C. Antoniou, Oral clindamycin and 365 rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year 366 follow-up, Clin Exp Dermatol, vol.41, pp.852-859, 2016.

C. Caro, R. D. Bianchi, and L. , Clindamycin alone may be enough. Is it time to abandon 368 rifampicin for hidradenitis suppurativa?, Br J Dermatol, vol.180, p.1262, 2019.

K. Armyra, A. Kouris, V. Markantoni, A. Katsambas, and G. Kontochristopoulos, Hidradenitis 370 suppurativa treated with tetracycline in combination with colchicine: a prospective series of 371 20 patients, Int J Dermatol, vol.56, pp.346-50, 2017.

A. Birgy, R. Cohen, C. Levy, P. Bidet, C. Courroux et al., Community faecal 373 carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in French 374 children, BMC Infect Dis, vol.12, p.315, 2012.

H. C. Ring, V. Sigsgaard, J. Thorsen, K. Fuursted, S. Fabricius et al., The 376 microbiome of tunnels in hidradenitis suppurativa patients, J Eur Acad Dermatol Venereol, vol.377, pp.1775-80, 2019.

, Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired 379 respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic 380 characteristics, Pharmacotherapy, vol.20, pp.245-56, 2000.

O. Join-lambert, F. Ribadeau-dumas, V. Jullien, M. D. Kitzis, J. P. Jais et al., , p.382

, Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa 383

, Age of patients (years), median

, Body mass index (kg.m -2 ), median

, Familial HS

, Age at onset of HS (years), median

, Duration of HS (years), median

, Patients with ? 1 flare/month, n (%) 23 (82) 409 N° of HS active lesions

V. Pain and . Median,

, Antibiotics, issue.89, p.25

, Rifampicin-clindamycin, n (%)

N. Pristinamycin, , p.14

, Tetracycline, issue.39, p.11

, Reported use of non-steroidal anti-inflammatory drugs, n (%)

, Local surgery, n (%), p.27

, Wide surgery, n (%), p.10